Literature DB >> 16497981

Pretreatment hemostatic markers of symptomatic intracerebral hemorrhage in patients treated with tissue plasminogen activator.

Dolores Cocho1, Montserrat Borrell, Joan Martí-Fàbregas, Joan Montaner, Mar Castellanos, Yolanda Bravo, Laura Molina-Porcel, Roberto Belvís, Jorge-Alberto Díaz-Manera, Alejandro Martínez-Domeño, María Martínez-Lage, Mónica Millán, Jordi Fontcuberta, Josep-Lluis Martí-Vilalta.   

Abstract

BACKGROUND AND
PURPOSE: Symptomatic intracerebral hemorrhage (ICH) is a major complication of thrombolysis in patients with acute ischemic stroke. We analyzed whether baseline hemostatic markers could predict symptomatic ICH (SICH).
METHODS: In a multicenter study of patients treated with intravenous tissue plasminogen activator (t-PA) within 3 hours of stroke onset, we analyzed the following variables: demographic data, vascular risk factors, blood glucose at admission, time from the onset of symptoms to t-PA infusion, blood pressure, neurological deficit measured by the National Institutes of Health Stroke Scale (NIHSS) score, early signs of ischemia on the baseline computed tomography (CT) scan, and protocol deviations. In blood samples, the following markers of coagulation/fibrinolysis were measured before treatment: fibrinogen, prothrombin fragments 1+2, Factor XIII, Factor VII, alpha2 antiplasmin, plasminogen activator inhibitor-1 (PAI-1), and thrombin-activatable fibrinolysis inhibitor. ICH was classified according to the European Cooperative Acute Stroke Study (ECASS) II criteria. SICH was defined as a parenchymal hematoma-1 (PH1) or PH2 type, associated with an increase in > or =4 points on the NIHSS score appearing within 36 hours after infusion.
RESULTS: We studied 114 patients. Mean age was 68.4+/-12.7 years, and 61% were men. The median baseline NIHSS score was 14. Mean time to treatment was 153+/-33 minutes. Eight patients had SICH (7%), and 18 patients (15.7%) had asymptomatic ICH. None of the baseline markers of coagulation/fibrinolysis were associated with SICH. In the multivariate analysis, only NIHSS on admission was an independent risk factor for SICH.
CONCLUSIONS: None of the hemostatic markers analyzed in our study predicted symptomatic cerebral hemorrhage in patients with ischemic stroke treated with t-PA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16497981     DOI: 10.1161/01.STR.0000206461.71624.50

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  18 in total

Review 1.  Hemorrhagic Transformation after Tissue Plasminogen Activator Reperfusion Therapy for Ischemic Stroke: Mechanisms, Models, and Biomarkers.

Authors:  Wei Wang; Mingchang Li; Qianxue Chen; Jian Wang
Journal:  Mol Neurobiol       Date:  2014-11-04       Impact factor: 5.590

Review 2.  Towards the identification of blood biomarkers for acute stroke in humans: a comprehensive systematic review.

Authors:  Nazeeha Hasan; Peter McColgan; Paul Bentley; Robert J Edwards; Pankaj Sharma
Journal:  Br J Clin Pharmacol       Date:  2012-08       Impact factor: 4.335

Review 3.  Hemorrhagic Transformation After Tissue Plasminogen Activator Treatment in Acute Ischemic Stroke.

Authors:  Chengli Liu; Jie Xie; Shanshan Sun; Hui Li; Tianyu Li; Chao Jiang; Xuemei Chen; Junmin Wang; Anh Le; Jiarui Wang; Zhanfei Li; Jian Wang; Wei Wang
Journal:  Cell Mol Neurobiol       Date:  2020-10-30       Impact factor: 5.046

Review 4.  Invited article: searching for oracles? Blood biomarkers in acute stroke.

Authors:  C Foerch; J Montaner; K L Furie; M M Ning; E H Lo
Journal:  Neurology       Date:  2009-08-04       Impact factor: 9.910

5.  RNA in blood is altered prior to hemorrhagic transformation in ischemic stroke.

Authors:  Glen C Jickling; Bradley P Ander; Boryana Stamova; Xinhua Zhan; Dazhi Liu; Lena Rothstein; Piero Verro; Jane Khoury; Edward C Jauch; Arthur M Pancioli; Joseph P Broderick; Frank R Sharp
Journal:  Ann Neurol       Date:  2013-09-10       Impact factor: 10.422

6.  Modified ASPECTS for DWI including deep white matter lesions predicts subsequent intracranial hemorrhage.

Authors:  Hiroyuki Kawano; Teruyuki Hirano; Makoto Nakajima; Yuichiro Inatomi; Toshiro Yonehara; Makoto Uchino
Journal:  J Neurol       Date:  2012-02-17       Impact factor: 4.849

7.  Hemorrhagic Transformation (HT) and Symptomatic Intracerebral Hemorrhage (sICH) Risk Prediction Models for Postthrombolytic Hemorrhage in the Stroke Belt.

Authors:  James E Siegler; Muhammad Alvi; Amelia K Boehme; Michael J Lyerly; Karen C Albright; Reza Bavarsad Shahripour; Pawan V Rawal; Niren Kapoor; April Sisson; J Thomas Houston; Anne W Alexandrov; Sheryl Martin-Schild; Andrei V Alexandrov
Journal:  ISRN Stroke       Date:  2013

8.  Low thrombin generation predicts poor prognosis in ischemic stroke patients after thrombolysis.

Authors:  Renáta Hudák; Edina G Székely; Katalin R Kovács; Attila Nagy; Gergely Hofgárt; Ervin Berényi; László Csiba; János Kappelmayer; Zsuzsa Bagoly
Journal:  PLoS One       Date:  2017-07-10       Impact factor: 3.240

9.  Effects of alteplase in the treatment of acute ischemic stroke.

Authors:  Josef Yayan
Journal:  Int J Gen Med       Date:  2012-09-06

Review 10.  Safety and efficacy of alteplase in the treatment of acute ischemic stroke.

Authors:  Giuseppe Micieli; Simona Marcheselli; Piera Angela Tosi
Journal:  Vasc Health Risk Manag       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.